Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Vixarelimab in Idiopathic Pulmonary Fibrosis: NCT05785624 Clinical Landscape Report 2026
15 October 2026
NCT05785624 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Misoprostol in Metabolic Dysfunction Associated Steatohepatitis: NCT05804305 Clinical Landscape Report 2026
15 October 2026
NCT05804305 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
NUV-001 in Anemia, Sickle Cell: NCT05789355 Clinical Landscape Report 2026
15 October 2026
NCT05789355 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sirolimus in Alveolitis, Extrinsic Allergic: NCT05798923 Clinical Landscape Report 2026
15 October 2026
NCT05798923 clinical landscape for Alveolitis, Extrinsic Allergic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HNC1058 in Idiopathic Pulmonary Fibrosis: NCT05803850 Clinical Landscape Report 2026
15 October 2026
NCT05803850 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AZD-2693 in Metabolic Dysfunction Associated Steatohepatitis: NCT05809934 Clinical Landscape Report 2026
15 October 2026
NCT05809934 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Nebokitug in Metabolic Dysfunction Associated Steatohepatitis: NCT05824156 Clinical Landscape Report 2026
15 October 2026
NCT05824156 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Taladegib in Idiopathic Pulmonary Fibrosis: NCT05817240 Clinical Landscape Report 2026
15 October 2026
NCT05817240 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AZD-9550 in Metabolic Dysfunction Associated Steatohepatitis: NCT05848440 Clinical Landscape Report 2026
15 October 2026
NCT05848440 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Anlotinib Dihydrochloride in Idiopathic Pulmonary Fibrosis: NCT05828953 Clinical Landscape Report 2026
15 October 2026
NCT05828953 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Denifanstat in Hepatic Insufficiency: NCT05835180 Clinical Landscape Report 2026
15 October 2026
NCT05835180 clinical landscape for Hepatic Insufficiency: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Evetifator in Amyotrophic Lateral Sclerosis: NCT05842941 Clinical Landscape Report 2026
15 October 2026
NCT05842941 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.